Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04797793 · ClinicalTrials.gov registry record · Early Phase 1
A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
A Early Phase 1 study of Acne Vulgaris, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 978
- Enrollment target
- 1
- Study location
NCT04797793 is a Early Phase 1 study of Acne Vulgaris that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 978 participants, above the 261-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (275% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04797793, a Early Phase 1 study of Acne Vulgaris, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 978 participants
- Enrollment target
- 1
- Study location
Study Summary
To demonstrate therapeutic equivalence and safety of adapalene gel 0.1% (Taro Pharmaceuticals U.S.A., Inc.) and Differin® Gel (Adapalene Gel 0.1%, Galderma) in the treatment of acne vulgaris.
Conditions Studied
Interventions
- DRUG Placebo Control
- DRUG Adapalene Gel 0.1%
- DRUG Differin® Gel (Adapalene 0.1%, Galderma)
Study Locations (1)
North Carolina
- Catawba Research, LLC - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 978 participants |
| Start Date | 2020-05-18 |
| Est. Completion | 2021-01-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04797793
The ClinicalTrials.gov registry entry for NCT04797793 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 978 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 261-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (275% higher). The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 3 interventions - of which Placebo Control is the first listed.
NCT04797793 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04797793 about?
NCT04797793 is a clinical study titled "A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris". To demonstrate therapeutic equivalence and safety of adapalene gel 0.1% (Taro Pharmaceuticals U.S.A., Inc.) and Differin® Gel (Adapalene Gel 0.1%, Galderma) in the treatment of acne vulgaris.
What is the current status of trial NCT04797793?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 978 participants. The study started on 2020-05-18. Estimated completion is 2021-01-08.
What conditions does trial NCT04797793 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT04797793?
The interventions under investigation include: Placebo Control (DRUG), Adapalene Gel 0.1% (DRUG), Differin® Gel (Adapalene 0.1%, Galderma) (DRUG).
Who is sponsoring clinical trial NCT04797793?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04797793 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Weekly Isotretinoin vs Tetracycline for Moderate Acne
RECRUITING · Early Phase 1
-
A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris
COMPLETED · Early Phase 1
-
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Laser Treatment of Moderate to Severe Acne Vulgaris
ACTIVE NOT RECRUITING · NA
-
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.